India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the ...

Innovent Biologics presents results from DREAMS-1 phase 3 study of mazdutide in Chinese adults with T2D at ADA Scientific Sessions: San Francisco Thursday, June 26, 2025, 14:00 Hr ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

Eli Lilly's obesity and Type 2 diabetes drug, Mounjaro, has gained approval from the Indian drug control authority for its ...

Eli Lilly is set to launch Mounjaro in KwikPen, a user-friendly, prefilled pen for weekly administration, in India, following ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a ...

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...

BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to ...

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.